It takes a tissue to make a tumor: Epigenetics, cancer and the microenvironment

Journal of Mammary Gland Biology and Neoplasia

Volumn 6, Issue 2, 2001, Pages 213-221

  Barcellos Hoff, Mary Helen ^a  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Carcinogenesis; Epigenetics; Ionizing radiation; Mammary; Stroma; Tissue

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CELL DAMAGE; CELL DISRUPTION; CELL FUNCTION; EPIGENETICS; GENE MUTATION; HUMAN; IONIZING RADIATION; NONHUMAN; RADIATION INJURY; SYSTEMATIC REVIEW; TISSUE REACTION; ANIMAL; BREAST TUMOR; ENVIRONMENT; EXTRACELLULAR MATRIX; FEMALE; GENETICS; NASA DISCIPLINE RADIATION HEALTH; NON-NASA CENTER; PHYSIOLOGY; REVIEW; STROMA CELL;

NASA DISCIPLINE RADIATION HEALTH; NON-NASA CENTER;

ANIMALS; BREAST NEOPLASMS; ENVIRONMENT; EXTRACELLULAR MATRIX; FEMALE; HUMANS; RADIATION, IONIZING; STROMAL CELLS;

EID: 0035320245     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011317009329     Document Type: Article

References (85)

1. M. J. Bissell and M. H. Barcellos-Hoff (1987). The influence of extracellular matrix on gene expression: Is structure the message? J. Cell Sci. 8:327-343.
2. G. B. Pierce, R. Shikes, and L. M. Fink (1978). Cancer: A Problem of Developmental Biology. Prentice-Hall, Inc., Englewood Cliffs, New Jersey.
3. C. Grobstein (1967). Mechanism of organogenetic tissue interaction. Natl. Cancer Inst. Monogr. 26:279-299.
4. K. Kratochwil (1969). Organ specificity in mesenchymal induction demonstrated in the embryonic development of the mammary gland of the mouse. Dev. Biol. 20:46-71.
5. E. Fuchs and J. A. Segre (2000). Stem cells: A new lease on life. Cell 100:143-155.
6. G. Evan and T. Littlewood (1998). A matter of life and cell death. Science 281:1317-1322.
7. E. Farber (1984). The multistep nature of cancer development. Cancer Res. 44:4217-4223.
8. R. A. Weinberg (1989). Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res. 49:3713-3721.
9. S. H. Kim, K. A. Roth, A. R. Moser, and J. I. Gordon (1993). Transgenic mouse models that explore the multistep hypothesis of intestinal neoplasia. J. Cell Biol. 123:877-893.
10. A. van den Hoof (1988). Stromal involvement in malignant growth. Adv. Cancer Res. 50:159-196.
11. M. Skobe and N. E. Fusenig (1998). Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl. Acad. Sci. U.S.A. 95:1050-1055.
12. K. W. Kinzler and B. Vogelstein (1997).Cancer-susceptibility genes. Gatekeepers and caretakers [news; comment]. Nature 386:761, 763.
13. K. W. Kinzler and B. Vogelstein (1998). Landscaping the cancer terrain [comment]. Science 280:1036-1037.
14. D. Hanahan and R. A. Weinberg (2000). The hallmarks of cancer. Cell 100:57-50.
15. M. Terzaghi and P. Nettesheim (1979). Dynamics of neoplastic development in carcinogen-exposed tracheal mucosa. Cancer Res. 39:3004-3010.
16. R. L. Ullrich (1986). The rate of progression of radiation-transformed mammary epithelial cells is enhanced after low-dose-rate neutron irradiation. Rad. Res. 105:68-75.
17. K. Kamiya, J. Yasukawa-Barnes, J. M. Mitchen, M. N. Gould, and K. H. Clifton (1995). Evidence that carcinogenesis involves an imbalance between epigenetic high-frequency initiation and suppression of promotion. Proc. Natl. Acad. Sci. U.S.A. 92:1332-1336.
18. G. Bauer (1996). Elimination of transformed cells by normal cells: A novel concept for the control of carcinogenesis. Histol. Histopathol. 11:237-255.
19. I. Engelmann and G. Bauer (2000). How can tumor cells escape intercellular induction of apoptosis? Anticancer Res. 20: 297-2306.
20. I. Engelmann, H. Eichholtz-Wirth, and G. Bauer (2000). Ex vivo tumor cell lines are resistant to intercellular induction of apoptosis and independent of exogenous survival factors. Anticancer Res. 20:2361-2370.
21. M. Terzaghi-Howe (1986). Inhibition of carcinogen-altered rat tracheal epithelial cell proliferation by normal epithelial cells in vivo. Carcinogenesis 8:145-150.
22. G.-W. Chang and M. Terzaghi-Howe (1998). Multiple changes in gene expression are associated with normal cell-induced modulation of the neoplastic phenotype. Cancer Res. 58:4445-4452.
23. M. M. Zutter, S. A. Santoro, W. D. Staatz, and Y. L. Tsung (1995). Re-expression of the α2β 1 integrin abrogates malignant phenotype of breast carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 92: 411-7415.
24. V. M. Weaver, O. W. Petersen, F. Wang, C. A. Larabell, P. Briand, C. Damsky, and M. J. Bissell (1997). Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137:231-245.
25. R. Bhatia, J. B. McCarthy, and C. M. Verfaillie (1996). Interferon-α restores normal β1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 87:3883-3891.
26. J. B. Little (2000). Radiation carcinogenesis. Carcinogenesis 21:397-404.
27. C. L. Limoli, M. I. Kaplan, J. Corcoran, M. Meyers, D. A. Boothman, and W. F. Morgan (1997). Chromosomal instability and its relationship to other end points of genomic instability. Cancer Res. 57: 557-5563.
28. E. I. Azzam, S. M. de Toledo, T. Gooding, and J. B. Little (1998). Intercellular communication is involved in the bystander regulation of gene expression in human cells exposed to very low fluences of α particles. Rad. Res. 150:497-504.
29. B. E. Lehnert and E. H. Goodwin (1997). Extracellular factor(s) following exposure to α particles can cause sister chromatid exchanges in normal human cells. Cancer Res. 57:2164-2171.
30. M. Chow and H. Rubin (1999). The cellular ecology of progressive neoplastic transformation: A clonal analysis. Proc. Natl. Acad. Sci. U.S.A. 96:2093-2098.
31. J. E. Trosko, C. C. Chang, and B. V. Madhukar (1990). Modulation of intercellular communication during radiation and chemical carcinogenesis. 123:241-251.
32. I. Tomlinson and W. Bodmer (1999). Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog. Nature Med. 5:11-12.
33. I. P. Tomlinson, M. R. Novelli, and W. F. Bodmer (1996). The mutation rate and cancer. Proc. Natl. Acad. Sci. U.S.A. 93: 4800-14803.
34. J. J. Decosse, C. L. Gossens, J. F. Kuzma, and D. Unsworth (1973). Breast cancer: Induction of differentiation by embryonic tissue. Science 181:1057-1058.
35. M. Cooper and H. Pinkus (1977). Intrauterine transplantation of rat basal cell carcinoma as a model for reconversion of malignant to benign growth. Cancer Res. 37:2544-2552.
36. S. L. Schor, A. M. Schor, A. Howell, and J. Haggie (1988). The possible role of abnormal fibroblasts in the phathogenesis of breast cancer. In M. A. Rich, J. C. Hager, and D. M. Lopez, (eds.), Breast Cancer: Scientific and Chemical Progress, Kluwer Academic Publishers, Boston, pp. 142-157.
37. S. L. Schor, A. M. Schor, A. Howell, and D. Crowther (1987). Hypothesis: Persistent expression of fetal phenotypic characteristics by fibroblasts is associated with an increased susceptibility to neoplastic disease. Expl. Cell Biol. 55:11-17.
38. S. L. Schor, A. M. Schor, P. Durning, and G. Rushton (1985). Skin fibroblasts obtained from cancer patients display foetal-like migratory behavior on collagen gels. J. Cell Sci. 73:235-244.
39. A. M. Schor, G. Rushton, J. E. Ferguson, A. Howell, J. Redford, and S. L. Schor (1994). Phenotypic heteogeneity in breast fibroblasts: Functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma. Int. J. Cancer 59:25-32.
40. J. A. Haggie, S. L. Schor, A. Howell, J. M. Birch, and R. A. S. Sellwood (1987). Fibroblasts from relatives of hereditary breast cancer patients display fetal-like behavior in vitro. Lancet 1: 455-1457.
41. D. Medina, F. Shepherd, and T. Gropp (1978). Enhancement of the tumorigenicity of preneoplastic mammary nodule lines by enzymatic dissociation. JNCI 60:1121-1126.
42. T. Sakakura, Y. Sakagami, and Y. Nishizuka (1979). Persistence of responsiveness of adult mouse mammary gland to induction by embryonic mesenchyme. Dev. Biol. 72:201-210.
43. T. Sakakura, Y. Sakagami, and Y. Nishizuka (1981). Accelerated mammary cancer development by fetal salivary mesenchyme isografted to adult mouse mammary epithelium. J. Natl. Cancer Inst. 66:953-959.
44. M. Y. Gordon, C. R. Dowding, G. P. Riley, J. M. Goldman, and M. F. Greaves (1987). Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 328:342-344.
45. M. H. Sieweke and M. J. Bissell (1994). The tumor promoting effect of wounding: A possible role for TGFβ induced fibrotic stroma. Crit. Rev. Oncogenesis 5:297-311.
46. B. Fisher and E. R. Fisher (1968). Role of host and tumor calcium in metastases. Cancer Res. 28:1753-1758.
47. D. S. Dolberg, R. Holingworth, M. Hertle, and M. J. Bissell (1985). Wounding and its role in RSV-mediated tumor formation. Science 230:676-678.
48. A. C. Schuh, S. F. Keating, F. S. Moneclaro, P. K. Vogt, and M. L. Breitman (1990). Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice. Nature 346:756-760.
49. A. Lochter, S. Galosy, J. Muschler, N. Freedman, Z. Werb, and M. J. Bissell (1997). Matrix metalloproteinase stomelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and premalignant phentoype in mammary epithelial cells. J. Cell Biol. 139:1861-1872.
50. N. Thomasset, A. Lochter, C. J. Sympson, L. R. Lund, D. R. Williams, O. Behrendtsen, Z. Werb, and M. J. Bissell (1998). Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. J. Amer. Sci. 153:457-467.
51. J. E. Trosko (1998). Hierarchcal and cybernetic nature of biologic systems and their relevance to homeostatic adaptation to low-level exposures to oxidative stress-inducing agents. Environ. Health Perspect. 106:331-339.
52. M. H. Barcellos-Hoff (1993). Radiation-induced transforming growth factor β and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res. 53:3880-3886.
53. M. H. Barcellos-Hoff, R. Derynck, M. L.-S. Tsang, and J. A. Weatherbee (1994). Transforming growth factor-β activation in irradiated murine mammary gland. J. Clin. Invest. 93:892-899.
54. E. J. Ehrhart, A. Carroll, P. Segarini, M. L.-S. Tsang, and M. H. Barcellos-Hoff (1997). Latent transforming growth factor-β activation in situ: Quantitative and functional evidence following low dose irradiation. FASEB J 11:991-1002.
55. M. H. Barcellos-Hoff (1998). How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Rad. Res. 150:S109-S120.
56. M. H. Barcellos-Hoff (1998). The potential influence of radiation-induced microenvironments in neoplastic progression. J. Mam. Gland Biol. Neoplasia 3:165-175.
57. M. H. Barcellos-Hoff and S. A. Ravani (2000). Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60:1254-1260.
58. J. Greenberger, M. Epperly, A. Zeevi, K. Brunson, K. Goltry, K. Pogue-Geile, J. Bray, and L. Berry (1996). Stromal cell involvement in leukemogenesis and carcinogenesis. In Vivo 10:1-17.
59. J. T. Leith and S. Michelson (1990). Tumor radiocurability: Relationship to intrinsic tumor eterogeneity and to the tumor bed effect. Invasion Metastasis 10:329-351.
60. L. T. Bemis and P. Schedin (2000). Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. Cancer Res. 60:3414-3418.
61. G. M. Hodges, R. M. Hicks, and G. D. Spacey (1977). Epithelial-stromal interactions in normal and chemical carcinogen-treated adult bladder. Cancer Res. 37:3720-3730.
62. R. S. Cha, W. G. Thilly, and H. Zarbl (1994). N-nitroso-N- ethylurea-induced rat mammary tumors arise from cells with preexisting oncogenic Hras1 gene mutations. PNAS 91:3749-3753.
63. A. Haimovitz-Friedman, I. Vlodavsky, A. Chaudhuri, L. Witte, and Z. Fuks (1991). Autocrine effects of fibroblast growth factor in repair of radiation damage in endothelial cells. Cancer Res. 51: 552-2558.
64. 1 arrest by cell-substratum interactions. Cancer Res. 57: 151-1156.
65. S. Kondo (1988). Altruistic cell suicide in relation to radiation hormesis. Int. J. Radiat. Biol. Phys. Chem. Med. 53:95-102.
66. C. Nathan and M. Sporn (1991). Cytokines in context. J.Cell Biol. 113:981-986.
67. A. B. Roberts, N. L. Thompson, U. Heine, C. Flanders, and M. B. Sporn (1988). Transforming growth factor-β: Possible roles in carcinogenesis. Brit. J. Cancer 57:594-600.
68. J. Massague, S. W. Blain, and R. S. Lo (2000). TGF-β signaling in growth control, cancer, and heritable disorders. Cell 103:295-309.
69. M. W. J. Ferguson (1994). Skin wound healing: Transforming growth factor β antagonists decrease scarring and improve quality. J. Interferon Res. 14:303-304.
70. G. S. Ashcroft, X. Yang, A. B. Glick, M. Weinstein, J. L. Letterio, D. E. Mizel, M. Anzano, T. Greenwell-Wild, S. M. Wahl, C. Deng, and A. B. Roberts (1999). Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nature Cell Biol. 1: 60-266.
71. T. Ohmori, J. L. Yang, J. O. Price, and C. L. Arteaga (1998). Blockade of tumor cell transforming growth factor-βs enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp. Cell Res. 245:350-359.
72. B. A. Teicher, Y. Maehara, Y. Kakeji, G. Ara, S. R. Keyes, J. Wong, and R. Herbst (1997). Reversal of in vivo drug resistance by the transforming growth factor-β inhibitor decorin. Int. J. Cancer 71:49-58.
73. T. Häufel, S. Dormann, J. Hanusch, A. Schwieger, and G. Bauer (1999). Three distinct roles for TGF-β during intercellular induction of apoptosis: A review. Anticancer Res. 19: 105-111.
74. M. H. Sieweke, N. L. Thompson, M. B. Sporn, and M. J. Bissell (1990). Mediation of wound-related Rous sarcoma virus tumorigenesis and TGF-β. Science 248:1656-1660.
75. G. Furstenberger, M. Rogers, R. Schnapki, G. Bauer, P. Hofler, and F. Marks (1989). Stimulatory role of transforming growth factors in multistage skin carcinogenesis: Possible explanation for the tumor-inducing effect of wounding in initiated NMRI mouse skin. Int. J. Cancer 43:915-921.
76. T. M. Fynan and M. Reiss (1993). Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit. Rev. Oncogen. 4:493-540.
77. D. F. Pierce, A. E. Gorska, A. Chythil, K. S. Meise, D. L. Page, R. J. Coffey, Jr., and H. L. Moses (1995). Mammary tumor suppression by transforming growth factor β1 transgene expression. Proc. Natl. Acad. Sci. U.S.A. 92:4254-4258.
78. W. Cui, D. J. Fowlis, S. Bryson, E. Duffie, H. Ireland, A. Balmain, and R. J. Akhurst (1996). TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86:531-542.
79. G. Portella, S. A. Cumming, J. Liddell, W. Cui, H. Ireland, R. J. Akhurst, and A. Balmain (1998). Transforming growth factor β is essential for spindle cell conversion of mouse skin carcinoma in vivo: Implications for tumor invasion. Cell Growth Differ. 9: 93-404.
80. C. Amendt, P. Schirmacher, H. Weber, and M. Blessing (1998). Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 17:25-34.
81. E. D. Hay (1995). An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1:8-20.
82. B. Tang, E. P. Bottinger, S. B. Jakowlew, K. M. Bangall, J. Mariano, M. R. Anver, J. J. Letterio, and L. M. Wakefield (1998). Transforming growth factor-β1 is a new form of tumor supressor with true haploid insufficiency. Nature Medicine 4:802-807.
83. M. Hojo, T. Morimoto, M. Maluccio, T. Asano, K. Morimoto, M. Lagman, T. Shimbo, and M. Suthanthiran (1999). Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397: 30-534.
84. 1 arrest, p53, and Rb. Cancer Res. 56:3645-3650.
85. A. Glick, N. Popescu, V. Alexander, H. Ueno, E. Bottinger, and S. H. Yuspa (1999). Defects in transforming growth factor-β signaling cooperate with a Ras oncogene to cause rapid aneuploidy and malignant transformation of mouse keratinocytes. Proc. Nat. Acad. of Sci. U.S.A. 96:14949-14954.